Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof
The present disclosure discloses a WDR5 protein-protein interaction inhibitor, including a compound having a structure represented by general formula (I). Experiments show that the inhibitor acts on a WDR5 protein and an interacting protein thereof including, but not limited to, MLL, selectively inhibits the proliferation of leukemia cells, and inhibits the methylation of H3K4 and the expression of downstream Hox/Meis-1 gene at the cellular level. The present disclosure also discloses a method for preparing the inhibitor and use thereof in the preparation of a drug for treating acute leukemia and other related diseases.
1. An aniline-based WDR5 protein-protein interaction inhibitor, comprising a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a hydrate, or a solvate thereof:
wherein X represents CH or N;
Y represents C or N;
R 1 , R 2 and R 3 are selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxyl, nitro, halo, cyano, aldehyde group, hydroxyl, or —NR 7 R 8 , wherein R 7 and R 8 represent hydrogen, or C 1 -C 4 alkyl, or R 7 and R 8 together form a 3- to 7-membered nitrogenous heterocycle formed by linking R 7 and R 8 ;
R 4 represents morpholinyl, piperazinyl, 4-substituted piperazinyl, 4-substituted homopiperazinyl, 3-substituted piperazinyl, or 2-substituted piperazinyl, wherein a substituent is C 1 -C 4 alkyl, 3- to 7-membered cycloalkyl, hydroxyalkyl, or phenyl;
R 5 represents nitro, amino, phenyl, substituted phenyl, 5- to 6-membered oxygenic or nitrogenous aromatic heterocycle, substituted 5- to 6-membered oxygenic or nitrogenous aromatic heterocycle, or —NHCOR 9 ; wherein R 9 represents hydroxyl, C 1 -C 6 alkoxy, phenyl, substituted phenyl, 5- to 6-membered oxygenic or nitrogenous aromatic heterocycle, or substituted 5- to 6-membered oxygenic or nitrogenous aromatic heterocycle, wherein a substituent is C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, —NHCOR 10 , —CONR 11 R 12 or —COOR 10 , wherein R 10 represents hydrogen, C 1 -C 6 alkyl, C 1 -C 6 amino-substituted alkyl, 3- to 7-membered cycloalkyl, 3- to 7-membered nitrogenous or oxygenic heterocycle, or phenyl; and R 11 and R 12 represent hydrogen, C 1 -C 6 alkyl, phenyl or substituted phenyl, or substituted or unsubstituted 3- to 7-membered nitrogenous or oxygenic heterocycle, or 3- to 7-membered nitrogenous or oxygenic heterocycle formed by linking R 11 and R 12 ; and R 6 represents hydrogen, halo, methyl, trifluoromethyl, amino, or substituted amino, wherein a substituent is C 1 -C 4 alkyl, or allyl.
2. The aniline-based WDR5 protein-protein interaction inhibitor according to claim 1 , wherein X represents CH or N, and Y represents C or N; wherein R 1 , R 2 and R 3 are selected from the group consisting of hydrogen, methyl, methoxy, nitro, halo, cyano, aldehyde group, or —NR 7 R 8 , wherein R 7 and R 8 represent hydrogen or C 1 -C 4 alkyl, or 3- to 5-membered nitrogenous heterocycle formed by linking R 7 and R 8 .
3. The aniline-based WDR5 protein-protein interaction inhibitor according to claim 1 , wherein R 4 represents morpholinyl, piperazinyl, or 4-substituted piperazinyl, wherein a substituent is methyl, ethyl, cyclopropyl, hydroxyethyl, or phenyl.
4. The aniline-based WDR5 protein-protein interaction inhibitor according to claim 1 , wherein R 5 represents nitro, amino, —NHCOR 9 , furyl, pyrimidinyl, pyridinyl, substituted triazolyl, or substituted phenyl, wherein a substituent is a mono- or di-substituted halo, —NHCOR 10 , —CONR 11 R 12 , or —COOR 10 , wherein R 9 represents phenyl, R 10 represents hydrogen, C 1 -C 6 alkyl, C 1 -C 6 amino-substituted alkyl, 3- to 7-membered cycloalkyl, 3- to 7-membered nitrogenous or oxygenic heterocycle, or phenyl; and R 11 and R 12 represent hydrogen, C 1 -C 6 alkyl, phenyl or substituted phenyl, substituted or unsubstituted 3- to 7-membered nitrogenous or oxygenic heterocycle, or 3- to 7-membered nitrogenous or oxygenic heterocycle formed by linking R 11 and R 12 .
5. The aniline-based WDR5 protein-protein interaction inhibitor according to claim 1 , wherein the pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt represented by general formula (I); wherein the inorganic acid salt is a hydrochloride, a hydrobromide, or a sulfate; and the organic acid salt is an acetate, a lactate, a succinate, a fumarate, a maleate, a citrate, a benzoate, a methanesulfonate, or a p-toluenesulfonate.
6. A pharmaceutical composition, comprising the aniline-based WDR5 protein-protein interaction inhibitor of formula I according to claim 1 and one or more pharmaceutical carriers, diluents and excipients.
7. A method of treating a condition related to a WDR5 enzyme function in an animal, comprising administering to the animal an effective amount of the compound of claim 1 .
8. The method of claim 7 , wherein the condition is a hematological tumor.
9. The method of claim 8 , wherein the hematological tumor is acute leukemia.
10. The compound of claim 1 , having the structure:
11. The compound of claim 1 , having the structure:
12. The compound of claim 1 , having the structure:
13. The compound of claim 1 , having the structure:
14. The compound of claim 1 , having the structure:
15. The compound of claim 1 , having the structure:
16. The compound of claim 1 , having the structure:
17. The compound of claim 1 , having the structure:
18. The compound of claim 1 , having the structure: